AI-generated analysis. Always verify with the original filing.
CAMP4 Therapeutics reported full year 2025 financial results with a net loss of $80.4 million and announced progress on its SYNGAP1 program, planning a Phase 1/2 trial as early as H2 2026. The company strengthened its balance sheet through a GSK collaboration and equity financing, extending its cash runway into 2028.
Event Type
Disclosure
Mandatory
Variant
8-K
and Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amende
and Exhibit 99.2 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the l
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by CAMP4 Therapeutics Corporation on March 5, 2026. 99.2 Corpo
| Metric | Value | Basis |
|---|---|---|
| Research and Collaboration Revenue | $3.50 | GAAP |
| Research and Development Expenses | $38.20 | GAAP |
| General and Administrative Expenses | $17.36 | GAAP |
| Net Loss | $80.40 | GAAP |
| Net Loss Per Share | $-2.65 | GAAP |
Material Agreement